AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) announces the launch of ...
TOKYO, Jan. 6, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) accepted ...
Zydus Life was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Mirabegron extended-release tablets and therefore is eligible for 180 days ...
Generic drugmaker Lupin has settled with Astellas Pharma a patent infringement dispute relating to overactive bladder drug Mirabegron. The company and its wholly owned U.S. subsidiary Lupin ...
Zydus Lifesciences US subsidiary Zydus Pharmaceuticals USA Inc has received final approval from the United States Food and Drug Administration USFDA to market Mirabegron Extended-Release Tablets USP ...
Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved mirabegron extended-release tablets, 50 mg, in US. Mirabegron ...
Pharma major Lupin Ltd on September 4 said it has launched its generic version of Mirabegron extended-release tablets used in the treatment of overactive bladder, following approval from the US health ...
The Mumbai-based drug maker Lupin has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement. Lupin's product is a generic ...
Shares of Lupin rose nearly 4 percent after the pharmaceutical major announced the launch of Mirabegron Extended-Release tablets (25 mg) in the United States, a drug which has over $1 billion in sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results